56R0 Stock Overview
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.82 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$4.18 |
| Beta | 0.91 |
| 1 Month Change | 0% |
| 3 Month Change | 1.39% |
| 1 Year Change | -54.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56R0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 1.9% |
| 1Y | -54.1% | -5.0% | 4.6% |
Return vs Industry: 56R0 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 56R0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 56R0 volatility | |
|---|---|
| 56R0 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 56R0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 56R0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 12 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.
NanoVibronix, Inc. Fundamentals Summary
| 56R0 fundamental statistics | |
|---|---|
| Market cap | €5.52m |
| Earnings (TTM) | -€4.94m |
| Revenue (TTM) | €682.29k |
8.1x
P/S Ratio-1.1x
P/E RatioIs 56R0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56R0 income statement (TTM) | |
|---|---|
| Revenue | US$752.00k |
| Cost of Revenue | US$585.00k |
| Gross Profit | US$167.00k |
| Other Expenses | US$5.62m |
| Earnings | -US$5.45m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.28 |
| Gross Margin | 22.21% |
| Net Profit Margin | -724.47% |
| Debt/Equity Ratio | 0% |
How did 56R0 perform over the long term?
See historical performance and comparison